Rationale and Design of Rivaroxaban Estimation With Warfarin in Atrial Fibrillation Patients With Coronary Stent Implantation (REWRAPS)-Reference-Cited by-同舟云学术

Rationale and Design of Rivaroxaban Estimation With Warfarin in Atrial Fibrillation Patients With Coronary Stent Implantation (REWRAPS)

Published:2022-12-09 Issue:12 Volume:4 Page:604-608
ISSN:2434-0790
Container-title:Circulation Reports
language:en
Short-container-title:Circ Rep

Author:

Ozaki Yukio¹,Kawai Hideki¹,Muramatsu Takashi¹,Harada Masahide¹,Takahashi Hiroshi²,Ishii Hideki³,Maekawa Yuichiro⁴,Ismail Tevfik F.¹,Amano Tetsuya⁵,Izawa Hideo¹,Murohara Toyoaki⁶

Affiliation:

1. Department of Cardiology, Fujita Health University (FHU) School of Medicine

2. Division of Medical Statistics, FHU

3. Department of Cardiovascular Medicine, Gunma University

4. Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine

5. Department of Cardiology, Aichi Medical University Hospital

6. Department of Cardiology, Nagoya University Graduate School of Medicine

Publisher

Japanese Circulation Society

Subject

Marketing,Organizational Behavior and Human Resource Management,Strategy and Management,Drug Discovery,Pharmaceutical Science,Pharmacology

Link

https://www.jstage.jst.go.jp/article/circrep/4/12/4_CR-22-0096/_pdf

Reference13 articles.

1. 1. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016; 375: 2423–2434.

2. 2. Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017; 377: 1513–1524.

3. 3. Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 2019; 380: 1509–1524.

4. 4. Kawai H, Watanabe E, Yamamoto M, Harigaya H, Sano K, Takatsu H, et al. Major bleeding complications related to combined antithrombotic therapy in atrial fibrillation patients 12 months after coronary artery stenting. J Cardiol 2015; 65: 197–202.

5. 5. Matsumura-Nakano Y, Shizuta S, Komasa A, Morimoto T, Masuda H, Shiomi H, et al. Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation. Circulation 2019; 139: 604–616.